Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2022

03-05-2021 | Colonoscopy | Original Article

A True Positive and a False Negative? The Dilemma of Negative Colonoscopy After a Positive Fecal Occult Blood Test

Authors: J. S. Hunt, C. Cock, E. L. Symonds

Published in: Digestive Diseases and Sciences | Issue 5/2022

Login to get access

Abstract

Introduction

Many colonoscopies following a positive fecal immunochemical test (FIT) will not identify a probable cause for fecal blood, and missed neoplasia is a concern. The study determined whether the absence of neoplasia at a FIT positive diagnostic colonoscopy was due to a missed lesion and whether the initial FIT hemoglobin (f-Hb) concentration could predict missed lesions.

Methods

This was a retrospective audit of patients who had undergone diagnostic colonoscopy after FIT screening (2 sample ≥ 20 µg Hb/g feces). Probable bleeding lesions including cancer, advanced adenoma, colitis, and angiodysplasia were considered a “positive colonoscopy outcome.” For those with a negative outcome, findings at the subsequent colonoscopy were assessed.

Results

There were 1087 good quality colonoscopies within 12 months of a positive FIT. In total, 171 (15.7%) patients had a positive outcome at the diagnostic colonoscopy. Subsequent colonoscopies of negative outcome cases (n = 418, median of 3.1y later) were reviewed; of these, there were 57 (13.6%) cases with a positive outcome. This included CRC in 0.5% (n = 2) and advanced adenoma in 11.7% (n = 49). High f-Hb and having both FIT samples ≥ 20 µg/g feces were associated with a positive outcome at the original diagnostic colonoscopy (p < 0.05). However, f-Hb was not predictive for a positive outcome at the subsequent colonoscopy by either maximum f-Hb (p = 0.768), total f-Hb (p = 0.459), or both FIT samples ≥ 20 µg/g (p = 0.091).

Conclusion

A small proportion of “false” positive FIT results had cancer or advanced adenoma found at the subsequent colonoscopy. A missed lesion could not be predicted by the initial FIT f-Hb.
Literature
6.
go back to reference AIHW, Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program. 2018: Australian Institute of Health and Welfare Canberra. AIHW, Analysis of bowel cancer outcomes for the National Bowel Cancer Screening Program. 2018: Australian Institute of Health and Welfare Canberra.
8.
go back to reference Cole SR, Tucker GR, Osborne JM et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198:327–330.CrossRef Cole SR, Tucker GR, Osborne JM et al. Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust. 2013;198:327–330.CrossRef
18.
go back to reference Bampton PA, Sandford JJ, Young GP. Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust. 2002;176:155–157.CrossRef Bampton PA, Sandford JJ, Young GP. Applying evidence-based guidelines improves use of colonoscopy resources in patients with a moderate risk of colorectal neoplasia. Med J Aust. 2002;176:155–157.CrossRef
20.
go back to reference Fenocchi E, Gaggero P, Rondán M et al. Usefulness of the fecal immunochemical test in the detection of advanced adenomas in subjects at average risk for colorectal cancer. Endoscopia. 2015;27:64–68.CrossRef Fenocchi E, Gaggero P, Rondán M et al. Usefulness of the fecal immunochemical test in the detection of advanced adenomas in subjects at average risk for colorectal cancer. Endoscopia. 2015;27:64–68.CrossRef
21.
go back to reference Australian Bureau of Statistic. Socio-economic Indexes for Areas: Technical Paper, 2016. 2016; cat. no. 2033.0.55.001:[ Australian Bureau of Statistic. Socio-economic Indexes for Areas: Technical Paper, 2016. 2016; cat. no. 2033.0.55.001:[
Metadata
Title
A True Positive and a False Negative? The Dilemma of Negative Colonoscopy After a Positive Fecal Occult Blood Test
Authors
J. S. Hunt
C. Cock
E. L. Symonds
Publication date
03-05-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 5/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06986-4

Other articles of this Issue 5/2022

Digestive Diseases and Sciences 5/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.